KLI

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

Metadata Downloads
Abstract
Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediate-term efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.
Author(s)
김승업이승원임영석최종기
Issued Date
2021
Type
Article
Keyword
EntecavirTenofovirHepatitis BCarcinomaHepatocellularEfficacyOutcome
DOI
10.1177/0284185120928931
URI
https://oak.ulsan.ac.kr/handle/2021.oak/7090
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_proquest_miscellaneous_2410364649&context=PC&vid=ULSAN&lang=ko_KR&search_scope=default_scope&adaptor=primo_central_multiple_fe&tab=default_tab&query=any,contains,Free-breathing%20contrast-enhanced%20upper%20abdominal%20MRI%20in%20children:%20comparison%20between%20Cartesian%20acquisition%20and%20stack-of-stars%20acquisition%20with%20two%20different%20fat-suppression%20techniques&offset=0&pcAvailability=true
Publisher
CLINICAL AND MOLECULAR HEPATOLOGY
Location
대한민국
Language
한국어
ISSN
2287-2728
Citation Volume
27
Citation Number
3
Citation Start Page
402
Citation End Page
412
Appears in Collections:
Medicine > Medicine
Authorize & License
  • Authorize공개
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.